41 results about "Desmosome" patented technology

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.

An anterior ocular segment related cell sheet or three-dimensional structure that have only a few structural defects as they have been recovered retaining the intercellular desmosome structure and the basement membrane-like protein between cell and substrate. The anterior ocular segment related cell sheet or three-dimensional structure is produced by a process comprising the steps of cultivating cells on a cell culture support comprising a substrate having its surface covered with a temperature responsive polymer having an upper or lower critical dissolution temperature of 0-80° C. with respect to water, optionally stratifying the layer of cultured cells by the usual method, and thereafter, (1) adjusting the temperature of the culture solution to either above the upper critical dissolution temperature or below the lower critical dissolution temperature, and further optionally (2) bringing the cultured anterior ocular segment related cell sheet or three-dimensional structure into close contact with a polymer membrane, and (3) detaching the sheet or three-dimensional structure together with the polymer membrane.

Modulating agents for inhibiting or enhancing desmosomal cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a desmosomal cadherin CAR sequence; (b) a non-peptide mimetic of a desmosomal cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a desmosomal cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a desmosomal cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating desmosomal cadherin-mediated cell adhesion in a variety of contexts are also provided.

The invention relates to the technical fields of tissue engineering and medical wound repair. At present, a living skin substitute constructed by using the materials of polylactic acid, polyglycolic acid, collagen, hyaluronic acid, and the like as a dermic bracket has the defects that on one hand, host materials are difficult to extract, the living skin substitute has complicated manufacturing technology and is expensive in cost and difficult to widely popularize and apply clinically; and on the other hand, the living skin substitute does not have a skin basilar membrane structure so that healed skin does not resist pressure and wear, and the living skin has unfirm adhesion to the epidermis and is easy to shed and break or form water blisters so that the structural and morphological development of the normal epidermis is influenced; and allogeneic acellular dermis is taken from cadaver skin and is limited in sources and expensive in cost, and thus clinical application is limited. The invention aims at providing a skin substitute which uses surface-finished and modified amnion as the basilar membrane and blood plasma as stroma, which has the advantages of wide material sources, low cost and simple preparation method. An animal experiment proves that the complete basilar membrane and hemidesmosomes can be retained in in-vivo transplantation, and the formation of an epidermal structural form is accelerated and promoted.

This invention relates to compounds, compositions, and methods useful for modulating Desmoglein (e.g, DSG1, DSG2, DSG3, and/or DSG4) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Desmoglein gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Desmoglein genes.

The invention provides a functional desmosome profile control agent and a preparation method and application thereof.The functional desmosome profile control agent is prepared from, by weight, 0.5%-11% of functional desmosome profile control agent particles, 0.1%-1% of guanidine gum and the balance water, wherein the total weight of the functional desmosome profile control agent is 100%, the functional desmosome profile control agent particles comprise inner cores, thermal swelling crosslinking resin films and semi-permeable protective films, the surfaces of the inner cores are wrapped by the thermal swelling crosslinking resin films, and the surfaces of the thermal swelling crosslinking resin films are wrapped by the semi-permeable protective films.The invention further provides the preparation method of the functional desmosome profile control agent and application of the functional desmosome profile control agent in oil well deep profile control.The functional desmosome profile control agent has the characteristics of temperature resisting, salt resisting, swelling delaying, crosslinking under heating and the like and is a novel profile control agent which is convenient to construct and easy to operate.

This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.

The present invention provides compositions and methods for treating disorders associated with epithelial tissues.

Perp is shown to mediate stratified epithelial development in vivo. Perp localizes specifically to desmosomes, adhesion junctions important for tissue integrity. In some embodiments of the invention, detection of autoantibodies specific for perp find use in the diagnosis of pemphigus. In other embodiments, agent that upregulate or mimic perp function are useful in treatment of such blistering diseases. In another embodiment, agents that inhibit perp function are useful in treating and preventing cancer.

Disclosed is a method for the diagnosis of cancer, which is characterized by detecting a DSG3 protein. It is found that the increase in the expression level of DSG3 is observed in lung cancer highly frequently at a gene or protein level. The method can be effected by using an antibody capable of recognizing a DSG3 protein. Also disclosed are a pharmaceutical composition, a cell proliferation inhibitor and an anti-cancer agent, each comprising an antibody capable of binding to DSG3 as an active ingredient. Further disclosed a method for inducing the cytopathy in a DSG3-expressing cell and a method for inhibiting the proliferation of a DSG3-expressing cell, each by contacting the DSG3-expressing cell with an antibody capable of binding to DSG3.

An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.

The invention provides a functional desmosome temporary plugging agent and a preparation method thereof. Counting the total mass of the functional desmosome temporary plugging agent at 100 percent, the functional desmosome temporary plugging agent is prepared from the following raw materials by weight percent: 45 to 58 percent of water, 0.2 to 0.4 percent of sodium carbonate, 0.05 to 0.1 percent of sodium hydroxide, 0.1 to 0.2 percent of methanol, 0.1 to 0.2 percent of octane, 0.3 to 0.5 percent of D-glucuronic acid, 0.04 to 0.1 percent of lauryl sodium sulfate, 1.3 to 1.7 percent of polyanionic celluloses, 0.2 to 0.4 percent of carboxymethyl celluloses, 0.2 to 0.5 percent of methyl tert-butyl ether and 40 to 50 percent of potassium formate, wherein the sum of the mass percent of all raw materials in the functional desmosome temporary plugging agent is 100 percent. The invention also provides the preparation method of the functional desmosome temporary plugging agent. The functional desmosome temporary plugging agent belongs to an oil-gas layer temporary plugging agent integrating shielding temporary plugging, oil-gas layer protection, leakage prevention and leakage plugging.

Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and/or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.

Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.

The invention relates to a composition for inhibiting melanin pigmentation and an application thereof. The composition comprises nicotinamide, inositol, papain and hesperidin extract products, The composition employs nicotinamide and inositol for blocking melanin and transferring black particles to cutin cells through dendritic cells, keratinocyte metabolism is accelerated; lipid-coated papain is employed, peeling and removal of dead cells on a cutin surface layer can be promoted, the melanin is discharged with shedding of cutin cells, update of the cuticle cells is excited; the hesperidin extract product can enhance the function for beautifying the skin, the cornification cellular structure is lifted, desmoplakin and keratin distribution can be improved, and the expression of CASEPASE-14 protein is promoted.

There is provided a method of isolating foetal cells from an isolated sample of maternal blood, the method comprising identifying cells having a different expression pattern of at least one foetal marker compared to the expression pattern of the marker in an equivalent maternal cell and selecting the identified cells, characterised in that the foetal marker is selected from: HSP-60, a monoamine oxidase, glutamine synthase, Ara-70, Ara-54, FLJ20202, DCN-I protein, RAB5A, HSP-7C, EF1A1, GRP78, MYL4, DnaJ homolog subfamily B member 14, Vinculin, Desmoplakin, AMMECR1-like protein, Extracellular matrix protein 2 precursor protein, uncharacterised protein Cxorf57, Peroxiredoxin 1, Peroxiredoxin 2. There is also provided a method of cultivating foetal cells and a foetal cell isolation kit.

The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.

Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one symptom of inflammation. The electrokinetically-generated fluids or therapeutic compositions and methods include electrokinetically-generated aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions.

The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.

The present invention provides a method and a pharmaceutical composition for treatment of skin diseases associated with accelerated comeodesmosomes degradation and/or weaker cell-cell adhesion, such as a peeling skin syndrome, Netherton syndrome, and atopic dermatitis.